TSC22D1 in pancreatic beta cells and C-MYC in cancer cells: Exploring therapeutic targets for diabetes and cancer
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
Since diabetes mellitus and cancer are among the world's major causes of illness and mortality, new treatment approaches are desperately needed. The control of pancreatic beta cell activity and the creation of designed cancer treatments are two different but related fields of molecular biology that are examined in this work. In the first part of the study, we identify TSC22D1 as a novel pancreatic beta cell function regulator. Using INS-1E cells, we demonstrate that TSC22D1 depletion enhances the expression of key beta cell identity genes such as INS1, INS2, Pdx1, Slc2a2, and Nkx6.1 while promoting glucose-stimulated insulin secretion without affecting intracellular insulin content. Mechanistically, we uncover a reciprocal interaction between TSC22D1 and FoxO1, which regulate glucose-responsive processes including mRNA processing, ribonucleoprotein complex biogenesis, and Golgi vesicle transport. These findings highlight TSC22D1 as a pivotal regulator of beta cell function with potential implications for diabetes treatment. The second part of the study focuses on the development of novel small-molecule inhibitors targeting the c-Myc/Max complex, a critical driver of tumourigenesis. A library of c-Myc inhibitors was screened across several cancer cell lines, including PANC1, MCF7, DU145, and A549. Among these, the inhibitor c-Myc-i7 exhibited remarkable anticancer potency, with IC50 values as low as 1.6 μM and up to 40 times greater efficacy than reference compounds. Notably, c-Myc-i7 demonstrated exceptional selectivity, showing a 37-fold and 59-fold preference for targeting prostate and breast cancer cells over healthy cells, respectively. Together, these discoveries point to the therapeutic potential of c-Myc inhibitors in cancer treatment and provide important new insights into the molecular control of beta cell activity, opening the door to new cancer and diabetes treatments.
Author
Sümbül Yıldırım
How to Cite
Sümbül Yıldırım (Doctorate thesis). TSC22D1 in pancreatic beta cells and C-MYC in cancer cells: Exploring therapeutic targets for diabetes and cancer, 2025, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- The relationship between mindfulness and sleep quality: The mediating role of smartphone addiction and bedtime procrastination(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Do borderline traits make people more sensitive? the relationship between borderline personality traits and mentalization capacity(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Kentli bakışaçısından bir kent markası yaratmak: İzmir ili örneği(2008)
- The effect of self-concept clarity on imposter phenomenon(2024)